156 related articles for article (PubMed ID: 38083992)
1. Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
Tamura D; Abe M; Hiraki H; Sasaki N; Yashima-Abo A; Ikarashi D; Kato R; Kato Y; Maekawa S; Kanehira M; Takata R; Maejima K; Sasagawa S; Fujita M; Suzuki Y; Nakagawa H; Iwaya T; Nishizuka SS; Obara W
Cancer Sci; 2024 Feb; 115(2):529-539. PubMed ID: 38083992
[TBL] [Abstract][Full Text] [Related]
2. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
[TBL] [Abstract][Full Text] [Related]
3. Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC.
Mu N; Jylhä C; Axelsson T; Sydén F; Brehmer M; Tham E
World J Urol; 2023 Dec; 41(12):3421-3427. PubMed ID: 37721600
[TBL] [Abstract][Full Text] [Related]
4. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.
Blumendeller C; Boehme J; Frick M; Schulze M; Rinckleb A; Kyzirakos C; Kayser S; Kopp M; Kelkenberg S; Pieper N; Bartsch O; Hadaschick D; Battke F; Stenzl A; Biskup S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33431630
[TBL] [Abstract][Full Text] [Related]
5. Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma.
Kogo R; Manako T; Iwaya T; Nishizuka S; Hiraki H; Sasaki Y; Idogawa M; Tokino T; Koide A; Komune N; Yasumatsu R; Nakagawa T
Cancer Med; 2022 Nov; 11(21):3960-3968. PubMed ID: 35352507
[TBL] [Abstract][Full Text] [Related]
6. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
7. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
[TBL] [Abstract][Full Text] [Related]
8. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Groeneweg JW; Roze JF; Peters EDJ; Sereno F; Brink AGJ; Paijens ST; Nijman HW; van Meurs HS; van Lonkhuijzen LRCW; Piek JMJ; Lok CAR; Monroe GR; van Haaften GW; Zweemer RP
Gynecol Oncol; 2021 Aug; 162(2):413-420. PubMed ID: 34083028
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.
Green EA; Li R; Albiges L; Choueiri TK; Freedman M; Pal S; Dyrskjøt L; Kamat AM
Eur Urol Oncol; 2021 Dec; 4(6):893-903. PubMed ID: 33975782
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling of Chinese patients with urothelial carcinoma.
Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Diagnostic Ureterorenoscopy on Intravesical Recurrence in Patients Undergoing Nephroureterectomy for Primary Upper Tract Urinary Carcinoma.
İzol V; Deger M; Ozden E; Bolat D; Argun B; Baltaci S; Celik O; Akgul HM; Tinay İ; Bayazit Y;
Urol Int; 2021; 105(3-4):291-297. PubMed ID: 33264798
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Validity of Urinary Pellet DNA Monitoring for the Diagnosis of Recurrent Bladder Cancer.
Abe M; Hiraki H; Tsuyukubo T; Ono S; Maekawa S; Tamura D; Yashima-Abo A; Kato R; Fujisawa H; Iwaya T; Park WY; Idogawa M; Tokino T; Obara W; Nishizuka SS
J Mol Diagn; 2024 Apr; 26(4):278-291. PubMed ID: 38301868
[TBL] [Abstract][Full Text] [Related]
14. Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma.
Huelster HL; Gould B; Schiftan EA; Camperlengo L; Davaro F; Rose KM; Soupir AC; Jia S; Zheng T; Sexton WJ; Pow-Sang J; Spiess PE; Daniel Grass G; Wang L; Wang X; Vosoughi A; Necchi A; Meeks JJ; Faltas BM; Du P; Li R
Eur Urol; 2024 Mar; 85(3):283-292. PubMed ID: 37802683
[TBL] [Abstract][Full Text] [Related]
15. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
[TBL] [Abstract][Full Text] [Related]
16. Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer.
Hassan F; Wang JH; O'Leary DP; Corrigan M; Redmond HP
Surg Oncol; 2024 Jun; 54():102060. PubMed ID: 38603927
[TBL] [Abstract][Full Text] [Related]
17. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Kosaka T; Mizuno R; Mikami S; Kikuchi E; Oya M
Cancer Sci; 2021 Mar; 112(3):1084-1094. PubMed ID: 33368857
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
[TBL] [Abstract][Full Text] [Related]
20. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
